The IDI – Details, episodes & analysis

What message is your prescription drug delivering?

Before manufacturers debut a new prescription drug they need to create a strategy to optimize coverage and commercialization. But part of that strategy consists of crafting a message that resonates with patients, providers and payers. And that’s where a lot of manufacturers get tripped up. 

Alex Mindlin of Valuate Health joins The IDI to explain how she validates manufacturers’ value messaging by combining strategic content and market research -- what she calls “creative market research.”

Follow Alex on LinkedIn.

Follow Valuate Health on LinkedIn or on the web.

Many pharmaceutical companies say attacking health inequities is a strategic objective, but addressing the topic is hard to do. Why is this so? 

This episode's guest, Elisa Remoundos,  Senior Vice President and Group Creative Director for Entrée Health, believes that for pharma and market access to tackle health inequities they need to rethink the social determinants of health that can have a huge impact on adherence, compliance, health outcomes, and societal burdens.

Elisa also wrote about SDoH and market acccess here. 

Follow Elisa on LinkedIn. 

Follow Valuate on LinkedIn or learn more here.

Every pharma company wants to analyze and leverage their data for other purposes. 

But what if you’re not a data scientist? Or maybe your data is messy; did you even know data can be messy?

Derek Tancredi and Terrill Paterson deal with these challenges all the time as they work with pharma and market access teams.

Derek is a consultant at Valuate Health with an MBA in Health Care Administration. Terrill Paterson is a Senior Analyst with Valuate. He holds a Masters in Statistics and a PhD in Environmental Science. 

Follow Derek on LinkedIn.

Follow Terrill on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

ChatGPT, the artificial intelligence tool that generates text and allows you to have human-like conversations, was released in November of last year. 

Today, you can ask  ChatGPT to write a business plan to commercialize market access for your new prescription drug -- and it will do so in seconds.

Bill Pittenger, SVP, Director of Digital Growth & Operations for Entrée Health, is experimenting with ChatGPT and other AI tools for market access. Bill explains how and why ChatGPT and other AI tools will transform market access for the better in today's episode.

Follow Bill Pittenger on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

Hub services sound great in theory. But in practice, hub services can be a challenge for the patient and the manufacturer. 

DeWayne Manning is a partner with Archbow Consulting and an expert on hub services. DeWayne has more than 25 years of experience advising clients on specialty products, reimbursement, patient access programs, business process optimization, technology integration, and data management  

Follow DeWayne Manning on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

The good news: The cancer death rate in America has fallen 33% since 1991. 

The bad news: The cost for treatment remains a huge barrier for some patients.

One recent study put the economic and human costs of cancer in adolescents and young adults at $23.5 billion overall -- nearly $260,000 per  patient.

To get a sense of how to improve access and affordability, The IDI host Ira Apfel spoke to John Hennessy and Matt Farber.

Hennessy is a Principal at Valuate and a former executive director of the Kansas City Cancer Center, and former executive director the community cancer program at the University of Kansas Hospital. 

Farber is the vice president for Enterprise Partnerships with OffScrip Health, one of the fastest-growing patient access, impact, and content influencers in the country.  

Follow John Hennessy on LinkedIn.

Follow Matt Farber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

A recent article in Pharmaceutical Executive listed 10 market access trends shaping the post-pandemic world -- and one of the contributors was Andrew Gottfried, CEO of Entree Health, an access and reimbursement communications agency. 

In a wide-ranging episode of The IDI, Andrew discussed global access and storytelling, the Inflation Reduction Act, the post-pandemic world, and more.

Connect with Andrew Gottfried on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com. 

Susan Weber is a Principal with Valuate Health. She recently authored a paper on the impact of the PIE Act, which you can read here.  

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

2022 was a year of uncertainty for pharma and market access. So we figured it was a good time to ask  payer executives for their thoughts on the subject -- and gain some insights from their responses. 

Susan Weber, today's guest on The IDI, wrote and supervised the survey. She's the best person to interpret the findings and draw some lessons for market access professionals. 

Connect with Susan Weber on LinkedIn.

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.

When President Biden signed the Inflation Reduction Act into law earlier this year, he set the stage for some of the biggest changes the pharmaceutical industry has seen in years. So how should pharma prepare for the IRA? 

Diane Petrone and Jim Kenney, principal consultants with Valuate Health, join The IDI to discuss what they're hearing from pharma clients about the IRA; which aspects of the IRA  will have the biggest impact on pharma; why removing some drug rebate calculations (as laid out in the IRA) is a big deal; and more. 

Follow Valuate on LinkedIn or visit us at ValuateHealth.com.